Pfizer Interest Coverage vs Operating Margin Analysis

PFE Stock  USD 27.78  0.19  0.69%   
Trend analysis of Pfizer Inc balance sheet accounts such as Total Stockholder Equity of 46.9 B, Property Plant And Equipment Net of 11.3 B, Net Debt of 75.8 B or Retained Earnings of 124.3 B provides information on Pfizer's total assets, liabilities, and equity, which is the actual value of Pfizer Inc to its prevalent stockholders. By breaking down trends over time using Pfizer balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

About Pfizer Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Pfizer Inc at a specified time, usually calculated after every quarter, six months, or one year. Pfizer Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Pfizer and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Pfizer currently owns. An asset can also be divided into two categories, current and non-current.

Pfizer Balance Sheet Chart

Pfizer Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Pfizer Inc uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Pfizer's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 28.9 B, whereas Property Plant And Equipment Net is forecasted to decline to about 11.3 B.

Total Assets

Total assets refers to the total amount of Pfizer assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Pfizer Inc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Pfizer balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pfizer Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Pfizer's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
As of March 28, 2024, Selling General Administrative is expected to decline to about 13.8 B. In addition to that, Discontinued Operations is expected to decline to about 5.1 M
 2021 2022 2023 2024 (projected)
Gross Profit50.5B66.0B29.3B30.4B
Total Revenue81.3B100.3B58.5B39.5B

Pfizer fundamental ratios Correlations

0.850.70.880.770.840.820.770.250.970.560.440.540.580.930.730.6-0.120.980.710.640.350.870.840.870.91
0.850.60.850.40.60.990.750.070.930.350.00.180.270.840.530.8-0.350.90.70.210.510.850.60.80.7
0.70.60.870.520.580.610.79-0.070.70.840.160.340.070.440.590.72-0.440.640.920.36-0.120.490.580.890.54
0.880.850.870.590.730.850.9-0.010.910.680.120.370.20.710.730.74-0.470.880.840.370.350.720.730.960.78
0.770.40.520.590.920.370.550.30.660.670.640.720.590.660.870.20.080.680.460.860.210.550.920.620.81
0.840.60.580.730.920.580.630.240.790.620.410.720.540.760.950.31-0.050.80.570.710.370.671.00.720.87
0.820.990.610.850.370.580.79-0.060.910.36-0.070.110.190.790.520.83-0.440.880.710.150.510.810.580.80.68
0.770.750.790.90.550.630.79-0.240.820.680.050.13-0.020.60.70.79-0.710.760.840.280.280.540.630.920.78
0.250.07-0.07-0.010.30.24-0.06-0.240.14-0.050.50.580.650.350.09-0.270.650.23-0.10.470.060.260.24-0.020.16
0.970.930.70.910.660.790.910.820.140.560.220.410.440.910.70.71-0.260.980.760.440.420.90.790.90.86
0.560.350.840.680.670.620.360.68-0.050.560.170.390.040.280.640.52-0.340.460.760.37-0.120.360.620.760.45
0.440.00.160.120.640.41-0.070.050.50.220.170.550.720.440.29-0.170.480.350.00.91-0.130.210.410.130.48
0.540.180.340.370.720.720.110.130.580.410.390.550.760.460.61-0.220.460.460.240.730.050.410.720.350.52
0.580.270.070.20.590.540.19-0.020.650.440.040.720.760.670.31-0.160.70.530.020.760.120.580.540.180.52
0.930.840.440.710.660.760.790.60.350.910.280.440.460.670.610.490.030.960.510.60.470.890.760.680.87
0.730.530.590.730.870.950.520.70.090.70.640.290.610.310.610.31-0.260.70.580.610.390.490.950.70.83
0.60.80.720.740.20.310.830.79-0.270.710.52-0.17-0.22-0.160.490.31-0.640.620.82-0.030.120.560.310.760.41
-0.12-0.35-0.44-0.470.08-0.05-0.44-0.710.65-0.26-0.340.480.460.70.03-0.26-0.64-0.17-0.530.34-0.170.05-0.05-0.48-0.21
0.980.90.640.880.680.80.880.760.230.980.460.350.460.530.960.70.62-0.170.680.550.460.890.80.840.9
0.710.70.920.840.460.570.710.84-0.10.760.760.00.240.020.510.580.82-0.530.680.22-0.10.530.570.890.57
0.640.210.360.370.860.710.150.280.470.440.370.910.730.760.60.61-0.030.340.550.220.030.380.710.380.7
0.350.51-0.120.350.210.370.510.280.060.42-0.12-0.130.050.120.470.390.12-0.170.46-0.10.030.430.370.20.43
0.870.850.490.720.550.670.810.540.260.90.360.210.410.580.890.490.560.050.890.530.380.430.670.730.68
0.840.60.580.730.921.00.580.630.240.790.620.410.720.540.760.950.31-0.050.80.570.710.370.670.720.87
0.870.80.890.960.620.720.80.92-0.020.90.760.130.350.180.680.70.76-0.480.840.890.380.20.730.720.76
0.910.70.540.780.810.870.680.780.160.860.450.480.520.520.870.830.41-0.210.90.570.70.430.680.870.76
Click cells to compare fundamentals

Pfizer Account Relationship Matchups

Pfizer fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets167.5B154.2B181.5B197.2B226.5B237.8B
Short Long Term Debt Total52.1B38.3B37.0B34.9B75.0B78.8B
Total Current Liabilities37.3B25.9B42.7B42.1B47.8B50.2B
Total Stockholder Equity63.1B63.2B77.2B95.7B89.0B46.9B
Property Plant And Equipment Net14.0B13.9B14.9B16.3B18.9B11.3B
Net Debt50.8B36.5B35.1B34.5B72.2B75.8B
Retained Earnings97.7B96.8B103.4B125.7B118.4B124.3B
Cash1.3B1.8B1.9B416M2.9B2.0B
Non Current Assets Total134.7B119.2B121.8B145.9B183.2B192.3B
Non Currrent Assets Other4.5B4.6B7.7B13.2B9.1B5.3B
Cash And Short Term Investments9.8B12.2B31.1B22.7B12.7B14.9B
Net Receivables12.1B11.2B15.7B14.5B11.2B8.7B
Common Stock Shares Outstanding5.7B5.6B5.7B5.7B5.7B6.3B
Liabilities And Stockholders Equity167.5B154.2B181.5B197.2B226.5B237.8B
Non Current Liabilities Total66.7B64.8B61.3B59.2B89.4B93.9B
Inventory8.3B8.0B9.1B9.0B10.2B5.2B
Other Current Assets2.6B3.4B3.8B5.0B9.3B9.7B
Other Stockholder Equity(23.4B)(22.3B)(20.8B)(22.2B)(21.9B)(20.8B)
Total Liab104.0B90.8B104.0B101.3B137.2B144.1B
Property Plant And Equipment Gross14.0B28.4B30.0B31.4B35.0B36.7B
Total Current Assets32.8B35.1B59.7B51.3B43.3B32.2B
Short Term Debt16.2B2.7B2.2B2.9B10.9B5.7B
Intangible Assets35.4B28.5B25.1B43.4B64.9B68.1B
Property Plant Equipment14.0B13.9B14.9B16.3B18.9B11.3B
Accounts Payable4.2B4.3B5.6B6.8B6.7B7.0B
Accumulated Other Comprehensive Income(11.6B)(11.7B)(5.9B)(8.3B)(8.0B)(7.6B)
Common Stock Total Equity468M470M473M476M478M474.0M
Short Term Investments8.5B10.4B29.1B22.3B9.8B9.3B
Common Stock468M470M473M476M478M474.0M
Other Liab29.7B26.6B22.6B23.3B26.9B22.1B
Other Assets4.2B4.3B5.6B6.8B6.7B5.0B
Long Term Debt36.0B37.1B36.2B32.9B60.5B63.5B
Good Will58.7B49.6B49.2B51.4B67.8B40.7B
Treasury Stock(110.8B)(111.0B)(111.4B)(114.0B)(114.5B)(108.8B)
Current Deferred Revenue5.8B6.3B3.1B2.5B2.7B3.9B
Net Tangible Assets(30.9B)63.2B77.2B95.7B89.0B93.5B
Noncontrolling Interest In Consolidated Entity303M235M262M256M274M265.1M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Dividend Share
1.64
Earnings Share
0.37
Revenue Per Share
10.366
Quarterly Revenue Growth
(0.41)
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.